Skip to main content
SDGR
NASDAQ Life Sciences

Schrödinger Lifts 2026 ACV and Drug Discovery Guidance as Q3 Revenue Grows 19%

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Health Tech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$30.747
Mkt Cap
$2.133B
52W Low
$10.945
52W High
$33.78
52W Position info
181% above low
Off High info
9.0% below high
Rel. Volume info
0.9× avg
Market data snapshot near publication time

SDGR has more than doubled off its 52-week low of $10.945.

Summary

Schrödinger posted Q3 revenue of $64.5M (+19%) and raised full-year ACV and drug discovery revenue guidance, while correcting an ASH abstract that overstated SGR-1505 development activity.


Key Events · Earnings and Guidance · SDGR

  • Q3 Revenue Up 19% to $64.5M

    Total revenue rose to $64.5M from $54.3M, with drug discovery revenue nearly doubling to $24.2M from $13.0M on a Structure Therapeutics milestone payment.

  • Full-Year Guidance Raised

    2026 ACV guidance lifted to $222M-$232M (12-17% growth) from $218M-$228M, and drug discovery revenue to $75M-$85M from $65M-$75M.

  • Net Loss Widens on Non-Cash Item

    Net loss was $37.7M versus $32.8M, driven by a $14.8M non-cash change in fair value of equity investments; operating expenses fell 13% to $64.4M.

  • ASH Abstract Corrected on SGR-1505

    The company said it has not initiated a combination study of SGR-1505 under its FDA-cleared protocol and is exploring strategic opportunities for the program; updated Phase 1 data will be presented at ASH December 12-15, 2026.


Analysis · SDGR · Life Sciences

Schrödinger beat on the top line and lifted both full-year targets: ACV is now guided to $222M-$232M (12-17% growth) versus the prior $218M-$228M, and drug discovery revenue to $75M-$85M from $65M-$75M. Q3 revenue of $64.5M rose 19%, with drug discovery nearly doubling to $24.2M on a Structure Therapeutics milestone. The offset: the quarter's net loss widened to $37.7M from $32.8M, largely a $14.8M non-cash mark-to-market swing on equity investments rather than an operating cash drain. Quietly, the filing also corrects the ASH abstract—there is no ongoing SGR-1505 combination study, and the company is instead seeking partners for that program, a reminder that the proprietary pipeline is being monetized rather than advanced in-house.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, SDGR was trading at $30.75 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.1B. The 52-week trading range was $10.95 to $33.78. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

SDGR - Latest Insights

SDGR
Nov 05, 2026, 3:00 AM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $29.50
Real-time Price: $22.90 info
Change: -$6.60 (-22%) info
Market Cap: $1.722B info
SDGR
Nov 04, 2026, 4:08 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $31.44
Real-time Price: $22.90 info
Change: -$8.54 (-27%) info
Market Cap: $1.722B info
SDGR
Nov 04, 2026, 4:05 PM EST
Source: BusinessWire
Importance Score:
8
Price at Filing: $28.72
Real-time Price: $22.90 info
Change: -$5.82 (-20%) info
Market Cap: $1.722B info
SDGR
Sep 09, 2026, 7:00 AM EDT
Source: BusinessWire
Importance Score:
7
Price at Filing: $20.03
Real-time Price: $22.90 info
Change: +$2.87 (+14%) info
Market Cap: $1.722B info
SDGR
Aug 05, 2026, 8:30 AM EDT
Source: BusinessWire
Importance Score:
7
Price at Filing: $15.71
Real-time Price: $22.90 info
Change: +$7.19 (+46%) info
Market Cap: $1.722B info